Top 10 rheumnow.com Competitors

lupus.bmj.com

Objective To evaluate the feasibility, usability and acceptability of implementing a treat-to-target (T2T) strategy supported by a Clinical Decision Support System (CDSS), in routine SLE outpatient care.Methods A 24-week, non-randomised, multicentre, clustered pilot study was conducted across four rheumatology outpatient centres. Adult patients with SLE were allocated by centre to either a T2T strategy supported by a CDSS (T2T-CDSS) or a routine outpatient care (ROC) group. The CDSS provided evidence-based treatment recommendations based on disease activity measures. Feasibility outcomes included recruitment and retention rates. Usability was assessed with the System Usability Scale (SUS), completed by physicians in the T2T-CDSS group. Acceptability was evaluated using the Treatment Satisfaction Questionnaire (TSQ) and qualitative feedback. Exploratory outcomes included disease activity, remission rates and treatment modifications.Results Of 91 screened patients, 38 were enrolled (recruitment rate 42%) and 35 completed the study (retention rate 92%). The SUS score for the CDSS was 73.8, indicating good usability. Global satisfaction scores on the TSQ were stable over time and comparable between groups. Remission was achieved at least once by 61% (11/18) of patients in the T2T-CDSS group and 59% (10/17) in the ROC group. Both treatment intensifications and de-escalations occurred more frequently in the T2T-CDSS group compared with ROC (83% vs 47%). Treatment intensifications were observed in 61% of patients in the T2T-CDSS group vs 29% in the ROC group. Treatment de-escalation, represented by glucocorticoid tapering, occurred in 39% of T2T-CDSS patients compared with 18% in ROC. No statistically significant differences were observed between groups in disease activity outcomes or remission rates.Conclusions Implementation of a T2T strategy supported by a CDSS in SLE outpatient care was feasible, usable and acceptable to patients and physicians. Although qualitative fe

sjogrenssyndromenews.com

Though she's felt agitated recently, columnist Rena Newman is trying to walk in forgiveness and find peace amid her health issues.

ped-rheum.biomedcentral.com

The syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA syndrome) is the most common cause of periodic fever in childhood. The current pharmacological treatment includes corticosteroids, which usually are efficacious in the management of fever episodes, colchicine, for the prophylaxis of febrile episodes, and other medication for which efficacy has not been proven so far. Tonsillectomy is an option for selected patients. Usually PFAPA syndrome resolves during adolescence, but there is increasing evidence that this condition may persist into adulthood.

rheuma.com.au

News and views on rheumatology for Australian doctors

skintherapyletter.com

Current and emerging hyperhidrosis treatments including sofpironium bromide, glycopyrronium wipes, botulinum toxin, targeted alkali thermolysis, microwave therapy, and laser options.

ccrheumatology.com

Congress of Clinical Rheumatology Privacy Policy Your privacy and safety of your data is important to us. This Privacy Policy document describes types of information that is or may be collected, used or shared by www.ccrheumatology.com when you visit, use or make a purchases. If you have any additional questions or require more information about […]

newyorkhipknee.com

This is a collection of frequently asked questions about Avascular Necrosis that were personally answered by Dr. Karkare. Read them here, and call (516) 735-4032 to make an appointment.

northfloridahandandwrist.com

If you have a pit, nodule or cord in your palm and/or the finger associated with it begins to draw into your palm, you may have Dupuytren’s Contracture (no special test is needed to diagnose this condition)

remissionmedical.com

According to a new report from the American College of Rheumatology (ACR), rheumatology care can save health systems more than $2,700 per patient per year.